Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume 17, Issue 9, Pages 884-892Publisher
WILEY
DOI: 10.1002/ejhf.319
Keywords
Heart failure; Ageing; Asia; Prevention
Categories
Funding
- Bayer Yakuhin, Ltd (Osaka, Japan)
- Daiichi Sankyo Co., Ltd (Tokyo, Japan)
- Novartis Pharma K.K. (Tokyo, Japan)
- Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan)
- Kowa Pharmaceutical Co., Ltd (Tokyo, Japan)
- Dainippon Sumitomo Pharma, Co., Ltd (Osaka, Japan),
- Nippon Boehringer Ingelheim Co., Ltd (Tokyo, Japan)
Ask authors/readers for more resources
Heart failure (HF) is epidemic in healthcare worldwide, including Asia. It appears that HF will become more serious in the near future, with the epidemiological transition and ageing of the population. However, in contrast to Western countries, information on HF epidemiology is still limited in Asia, particularly in South Asia. In this review, we will briefly summarize available information regarding the current and future burden of HF in Asia, which indicates the importance of both primary prevention of underlying diseases of HF and secondary prevention, including management of ischaemic HF, HF with preserved EF, and HF in the elderly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available